I was about to post the info. Thanks.
No time now to listen to the abbvie presentation, but doesn't this also suggest that ENTA has also decided whether to participate in development, or to simply stay in the same royalty mode as w/ 450?
If there is no news today, there should be soon.
I am dying to see the trial design and cohorts in the trial.
Luly in a presentation Sept 4 (if memory serves) repeated that both Abbvie and Enta believe that a nuke is NOT needed for a DAA combo to be competitive.
This suggests to me that they have had a good result in 2a trials and may have a treatment program which redefines the notion that nukes are necessary.
On the other hand, they really have not yet coupled the two compounds in dosing together. I was really a little mystified at the 2a trial design. One also notes that they have really been pretty tight lipped on results or hype in contrast to other companies.
This *should* be a positive catalyst for share price.
News 
Market Data 
Discover 
